Results 151 to 160 of about 1,864,473 (295)

Improving obesity management: Insights from the ACTION Switzerland survey of people with obesity, physicians and dietitians

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
PwO, people with obesity. Summary ACTION Switzerland (NCT05232786) examined obesity‐related perceptions, attitudes, behaviours and potential barriers to treatment among people with obesity (PwO) and healthcare professionals (HCPs). In March/April 2022, adult PwO (body mass index ≥30 kg/m2, per self‐reported height/weight) and physicians/certified ...
Dominique Durrer   +6 more
wiley   +1 more source

Changes in gastrointestinal motility and gut hormone secretion after Roux‐en‐Y gastric bypass and sleeve gastrectomy for individuals with severe obesity

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink   +4 more
wiley   +1 more source

Bariatric Surgery

open access: yes, 2019
Childhood Obesity continues to be on the rise and causes serious health consequences. In this podcast, Dr. Jason Fraser discusses the Bariatric Surgery program at Children\u27s Mercy.
Fraser, Jason D, Smith, Michael
core   +1 more source

Cohort Study on 5-Year Reoperation Rates: Total Ankle Arthroplasty and Ankle Arthrodesis in Patients with Prior Bariatric Surgery

open access: yesFoot & Ankle Orthopaedics
Category: Ankle; Ankle Arthritis Introduction/Purpose: Obesity is an ongoing public health epidemic with wide-ranging implications for orthopaedic surgery. Bariatric surgery has been shown to be an effective method for weight reduction.
Sanjay Kubsad BS   +5 more
doaj   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton   +4 more
wiley   +1 more source

Prurigo Pigmentosa – an increasingly diagnosed dermatological condition associated with ketogenic diet

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
SUMMARY Prurigo pigmentosa (PP) is a rare inflammatory dermatosis, clinically characterized by intensely pruritic, erythematous papules and papulovesicles, with reticular hyperpigmentation upon healing. We herein report four cases in adults of different ethnic backgrounds, in which the disease was associated with ketogenic metabolic states due to ...
Antigona Aliu   +7 more
wiley   +1 more source

Type 2 diabetes remission following a comprehensive metabolic program including surgery in adults with BMI ≥50 kg/m2 versus BMI <50 kg/m2

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Previous reports have suggested that higher baseline BMI (bBMI) or %excess weight loss (EWL) are independent predictors of type 2 diabetes mellitus (T2DM) remission after metabolic bariatric surgery (MBS). However, %EWL appears lower in individuals with bBMI ≥50 kg/m2 than those with lower bBMI.
Xi May Zhen   +12 more
wiley   +1 more source

Real‐world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

open access: yesDiabetic Medicine, EarlyView.
Abstract Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Jack E. Carruthers   +8 more
wiley   +1 more source

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann   +3 more
wiley   +1 more source

Acute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP‐1 and Glycaemic Responses in Post‐Bariatric Hypoglycaemia: A Randomised Crossover Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate the acute effects of acarbose and canagliflozin, alone and in combination, on postprandial total GLP‐1 and glycaemic responses during a mixed meal test in adults with post‐bariatric hypoglycaemia (PBH). Materials and Methods This single‐centre, randomised, four‐period crossover physiological study included 12 adults with PBH ...
Wei Yang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy